Tumor vaccines designed based on European and American cohorts may not be well-matched for Chinese patients: Ningshi Biotech is betting on population-specific vaccines with antigens tailored for the Chinese population.
Suzhou Ningshi Biotechnology Co., Ltd. (hereinafter referred to as Ningshi Biotech) is advancing a population-based therapeutic oncology vaccine codenamed AHV-201, and is seeking investors for its RMB 30 million seed round financing. Targeting highly prevalent solid tumors in China, the product adopts a fixed multi-epitope antigen combination, and is planned to be used in combination with PD-1/PD-L1 inhibitors, applicable to patients with HLA matching and positive antigen expression. Ningshi Biotech judges that the antigen design of mainstream international vaccine pipelines is built on European and American population cohorts, which has systematic mismatches with the Chinese population at three levels: HLA spectrum, somatic mutation profile and tumor etiology, and there is still a lack of systematic layout for this gap at present.
Population Mismatch Neglected by International Pipelines
Immune checkpoint inhibitors have reshaped the landscape of tumor treatment, but a considerable proportion of patients still do not respond. Ningshi Biotech proposes in its business plan that for most non-responding patients, the checkpoint pathway has been effectively blocked, and the real gap lies in the upstream, that is, the lack of a sufficient number and specific antigen-reactive T cells in the body, which is exactly the link that therapeutic oncology vaccines aim to fill.
The antigen design of vaccines must match the HLA (human leukocyte antigen) of the target population, because the binding of peptides to MHC molecules is allele-specific. According to Ningshi Biotech's business plan, the antigens of mainstream international pipelines are built on European and American population cohorts: the frequency of the HLA-A02:01 allele, which is highly prevalent in the European population, is about 27.1%, while the highest frequency allele HLA-A11:01 in the Chinese Han population accounts for about 22.9%, and the frequency of A*02:01 in the Chinese Han population is only about 12%. Antigens designed for European and American populations may not stably bind to the MHC groove in Chinese patients, making it difficult for T cells to be effectively activated. In addition, the Chinese population also has systematic differences with European and American populations in terms of somatic mutation profiles and tumor etiology, which has formed a consensus in the industry.
The market space on the demand side is also considerable. According to data from the National Cancer Center, there were approximately 4.8247 million new cases of malignant tumors and 2.5742 million deaths in China in 2022, both ranking first in the world. The five cancer types covered in the first phase of Ningshi Biotech, namely lung cancer, colorectal cancer, liver cancer, gastric cancer and esophageal cancer, collectively account for about 67.5% of all cancer deaths according to the 2022 mortality data from the National Cancer Center. Structural differences are more worthy of attention: liver cancer in China is mainly related to hepatitis B, and the incidence of gastric cancer and esophageal squamous cell carcinoma is significantly higher than that in Europe and the United States, and these cancer types have long not been prioritized in international vaccine pipelines. For a vaccine centered on adaptation to the Chinese population, this is not only an unmet clinical need, but also a differentiated market space.
An Intermediate Solution of Fixed Multi-Epitope Combination
AHV-201 is a population-based therapeutic oncology vaccine targeting highly prevalent solid tumors in China. Different from personalized vaccines customized case by case, it adopts a fixed multi-epitope antigen combination, which can be prepared in batches and released in a standardized manner; its clinical positioning is to be used in combination with PD-1/PD-L1, and the target population is screened through HLA typing, antigen expression, immune microenvironment status and previous treatment history. The product has clear boundaries: it does not sell algorithm platforms or testing services externally, nor does it redesign and produce personalized vaccines for each patient; its indications are not limited to post-operative adjuvant treatment, and the first phase targets patients with advanced, recurrent or progressive disease after standard treatment.
In the screening of candidate antigens, the team has established an auditable funnel: 150 candidate antigens are first computationally optimized (multi-modal evidence integration and presentation prediction) to 40, then reduced to 15 through in vitro primary screening (PBMC immunogenicity ELISpot), followed by safety filtering of paired paracancerous tissues to exclude normal tissue expression, and finally a set of main candidate combinations is frozen with a backup pool reserved. In terms of engineering, crude screening adopts low-purity small-scale synthesis, and only the final 15 candidates are subjected to high-purity scale-up, so the polypeptide synthesis cost is controlled at RMB 390,000.
This solution is at the middle position of the industry's technical route. The mainstream routes of therapeutic oncology vaccines have a trade-off between the matching accuracy of antigens and the target population and the degree of scalability: personalized neoantigen vaccines (such as mRNA-4157) are highly matched with patients' mutation profiles. In August 2026, Moderna and Merck announced that the Phase III trial of mRNA-4157 combined with Pembrolizumab has reached the primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB to IV melanoma, but the cycle and cost of case-by-case preparation cannot cover the scale of Chinese patients; off-the-shelf shared antigen vaccines can be scaled up with controllable costs, but the antigen selection is relatively rough and lacks population stratification. AHV-201 chooses to sacrifice the matching degree at the individual level in exchange for population-level adaptation and scalability of the fixed combination.
The track is heating up. According to public information, Orient Life Biotech's therapeutic HPV vaccine VGX-3100 reached a total exclusive cooperation of RMB 800 million with Fosun Pharma in January 2026; NeoCura Bio's personalized neoantigen vaccine XH001 was approved for clinical use in 2025 and launched the Phase I trial in the same year. For Ningshi Biotech, which is still in the seed round, this not only means verified market expectations, but also requires prudent expectation management. At present, the project is in the pre-clinical R&D stage, the antigen discovery and multi-modal integrated analysis pipeline has completed methodological verification on the UK cohort, and the construction of the candidate antigen pool and the design of the in vitro verification scheme have been completed; this round of financing corresponds to 18 to 24 months of key pre-submission verification.
Exchanging Data for Outcomes, Exchanging Assets for Licensing
In terms of business model, Ningshi Biotech cooperates with tertiary hospitals in a way of zero fee, no data outbound and outcome return: it returns the full set of multi-modal integrated analysis results for free, jointly publishes papers under co-authorship, and jointly applies for funds, in exchange for existing paired tumor and paracancerous sequencing data, real HLA spectrum of the Chinese population, clinical annotations and follow-up outcomes, forming auditable and due-diligence accessible data assets. The cooperation does not charge fees, no new sampling is required, and the clinical process is not changed. Data is stored and analyzed domestically, and will be destroyed as agreed after the cooperation period expires. Downstream, value is realized through pharmaceutical assets: before submission, the project is advanced through equity financing and strategic cooperation on the basis of candidate combinations, immunological data, animal efficacy and patents; after Phase I, with human safety and immunogenicity data, regional licensing, co-development and milestone payments can be negotiated; after Phase II, with efficacy signals and biomarker population definition as chips, global licensing, mergers and acquisitions or commercialization cooperation will be sought. Its business plan clearly states that it will not take algorithm services, testing services or research outsourcing as its source of revenue.
In terms of team, the core team of Ningshi Biotech has a total of six members, who are from the University of Oxford, Imperial College London, the National University of Singapore, University College London and Peking University respectively, covering antigen science and clinical translation, antigen preparation and characterization, artificial intelligence modeling, finance and business analysis. Zhang Aihan, CEO, is a postdoctoral fellow in the Department of Oncology, University of Oxford, and holds a doctorate from University College London; Shen Jiashu, Chief Scientific Officer, received his bachelor's degree from Peking University, and his doctorate and postdoctoral fellowship from the University of Oxford. He once served as co-founder of a start-up company and consultant for pharmaceutical enterprises, with practical experience in drug development, clinical trials and business development. The team also truthfully disclosed the gaps: there are no full-time personnel in the pharmaceutical (CMC) and regulatory modules, which are planned to be resolved through senior consultants and the recruitment budget of this round. According to Qixinbao information, Ningshi Biotech was registered and established in Suzhou High-tech Zone in August 2026.
This round of RMB 30 million seed round financing corresponds to an 18-24 month pre-submission verification path, covering six stages in sequence: candidate discovery and data assets, in vitro immunogenicity primary screening, candidate combination freezing and animal efficacy, CMC lab-scale test and quality research, safety and stability, pre-submission documents and Phase I protocol, and go/no-go decision points are set at the 6th, 12th and 18th months. In terms of financing terms, the company plans to transfer 15% to 20% of its equity, with a pre-money valuation of RMB 120 million to 170 million (to be negotiated), a 15% option pool established before investment, a capital period of 18 to 24 months with a 6-month buffer reserved; the funds are mainly invested in immunology experiments and samples, CMC and quality research, team and operation, data and computing, safety and registration, intellectual property and other directions.
It should be noted that the project is in the pre-clinical stage, and there is no proprietary human immunogenicity data and animal efficacy data yet; the cooperation with many tertiary hospitals is still in the stage of scheme communication, and no formal agreement has been signed; the first batch of patents are being written. Ningshi Biotech truthfully lists the above matters as ongoing or unfinished matters, and releases funds in stages according to milestones, corresponding to closing each item one by one. This management method of putting uncertainties in advance is the execution discipline worthy of attention for seed round projects.
The global oncology vaccine track is entering an acceleration period. From personalized neoantigens to shared antigens, the competition of various technical routes ultimately has to answer the same question: what kind of vaccines do Chinese patients need. The route given by Ningshi Biotech is to design antigens for the population first, and then develop scalable products. For a seed round company, whether it can obtain in vitro immunogenicity, animal efficacy and CMC research data according to milestones in the next 18 to 24 months will be the key to verify the feasibility of this route.